James Investment Research’s ANI Pharmaceuticals ANIP Stock Holding History

James Investment Research’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$385K	Hold	4,650	–	–	0.04%	292
2026 Q1	$358K	Buy	4,650 +7	+0.2%	+$546	0.04%	277
2025 Q4	$367K	Hold	4,643	–	–	0.04%	279
2025 Q3	$425K	Buy	4,643 +568	+14%	+$46.3K	0.05%	265
2025 Q2	$266K	Hold	4,075	–	–	0.03%	283
2025 Q1	$273K	Hold	4,075	–	–	0.03%	277
2024 Q4	$225K	Hold	4,075	–	–	0.03%	291
2024 Q3	$243K	Buy	+4,075	New	+$249K	0.03%	288

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

James Investment Research's ANIP Position: Q2 2026 in Review

James Investment Research held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 4,650 shares worth $385K. The position accounts for 0.04% of the portfolio, ranked #292.

James Investment Research first reported a position in ANIP in Q3 2024 and has held it in 8 quarters since. The position peaked at $425K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

James Investment Research held 4,650 shares of ANI Pharmaceuticals worth $385K as of Q2 2026.
James Investment Research left its ANI Pharmaceuticals share count unchanged in Q2 2026.
ANI Pharmaceuticals made up 0.04% of James Investment Research's portfolio in Q2 2026, its #292 holding.
James Investment Research first reported a position in ANI Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
James Investment Research's ANI Pharmaceuticals position peaked at $425K in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on James Investment Research's 13F filing for Q2 2026, filed 24 Jul 2026.